van 't Veer L - Search Results

1

Equivalence of MammaPrint array types in clinical trials and diagnostics.

Beumer I, Witteveen A, Delahaye L, Wehkamp D, Snel M, Dreezen C, Zheng J, Floore A, Brink G, Chan B, Linn S, Bernards R, van 't Veer L, Glas A. Beumer I, et al. Breast Cancer Res Treat. 2016 Apr;156(2):279-87. doi: 10.1007/s10549-016-3764-5. Epub 2016 Mar 22. Breast Cancer Res Treat. 2016. PMID: 27002507 Free PMC article.

2

E2F-5, a new E2F family member that interacts with p130 in vivo.

Hijmans EM, Voorhoeve PM, Beijersbergen RL, van 't Veer LJ, Bernards R. Hijmans EM, et al. Mol Cell Biol. 1995 Jun;15(6):3082-9. doi: 10.1128/MCB.15.6.3082. Mol Cell Biol. 1995. PMID: 7760804 Free PMC article.

3

N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa B.

van 't Veer LJ, Beijersbergen RL, Bernards R. van 't Veer LJ, et al. EMBO J. 1993 Jan;12(1):195-200. doi: 10.1002/j.1460-2075.1993.tb05645.x. EMBO J. 1993. PMID: 8428579 Free PMC article.

4

A functional assay in yeast for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma.

van Dijk MA, Floore AN, Kloppenborg KI, van 't Veer LJ. van Dijk MA, et al. Cancer Res. 1997 Aug 15;57(16):3478-85. Cancer Res. 1997. PMID: 9270016

5

ATM germline mutations in classical ataxia-telangiectasia patients in the Dutch population.

Broeks A, de Klein A, Floore AN, Muijtjens M, Kleijer WJ, Jaspers NG, van 't Veer LJ. Broeks A, et al. Hum Mutat. 1998;12(5):330-7. doi: 10.1002/(SICI)1098-1004(1998)12:5<330::AID-HUMU6>3.0.CO;2-H. Hum Mutat. 1998. PMID: 9792409

6

Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells.

Lambrechts AC, Bosma AJ, Klaver SG, Top B, Perebolte L, van' t Veer LJ, Rodenhuis S. Lambrechts AC, et al. Breast Cancer Res Treat. 1999 Aug;56(3):219-31. doi: 10.1023/a:1006261731125. Breast Cancer Res Treat. 1999. PMID: 10573113

7

ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ. Broeks A, et al. Am J Hum Genet. 2000 Feb;66(2):494-500. doi: 10.1086/302746. Am J Hum Genet. 2000. PMID: 10677309 Free PMC article.

8

Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations.

Broeks A, Russell NS, Floore AN, Urbanus JH, Dahler EC, van T Veer MB, Hagenbeek A, Noordijk EM, Crommelin MA, van Leeuwen FE, van T Veer LJ. Broeks A, et al. Int J Radiat Biol. 2000 May;76(5):693-8. doi: 10.1080/095530000138367. Int J Radiat Biol. 2000. PMID: 10866292

9

Gene expression profiling predicts clinical outcome of breast cancer.

van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. van 't Veer LJ, et al. Nature. 2002 Jan 31;415(6871):530-6. doi: 10.1038/415530a. Nature. 2002. PMID: 11823860

10

A gene-expression signature as a predictor of survival in breast cancer.

van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. van de Vijver MJ, et al. N Engl J Med. 2002 Dec 19;347(25):1999-2009. doi: 10.1056/NEJMoa021967. N Engl J Med. 2002. PMID: 12490681 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

455 results

Search Page

Filters